SINGAPORE: Recent breakthroughs in Chikungunya research spearheaded by scientists at A*STAR’s Singapore Immunology Network (SIgN) have made great strides in the battle against the infectious disease.
Working in close collaborations with Singapore clinician-scientists and international researchers, Dr Lisa Ng, Principal Investigator of the Chikungunya research group at SIgN, led the team to discover a direct biomarker which serves as an early and accurate prognosis of patients who have a higher risk of the more severe form of Chikungunya fever (CHIKF).
This means that doctors can now quickly and accurately identify patients at risk, facilitating a more targetted treatment and clinical care at the onset of the disease.
Chikungunya fever, caused by the Chikungunya virus (CHIKV), is a mosquito-borne, infectious disease endemic to Southeast Asia and Africa.
Since its re-emergence in 2005, CHIKV infection has spread to nearly 20 countries to infect millions.
Singapore, for instance, was hit twice by Chikungunya fever outbreaks in January and August 2008.
Commenting on the breakthrough, Dr Ng said, “Long-term treatment required for the chronic joint pain in Chikungunya-infected patients places social and economic burden for both the patients and the public healthcare system.
“We are excited that the mechanistic insights gained through our collaborative research with the local hospitals and international research partners have led to discovery of ‘new weapons’ to tackle Chikungunya more effectively,” she said. — Bernama